David Royston, MD

Articles

Evaluating the Role of Serine Protease Inhibition in the Management of Tumor Micrometastases

Joe B. Putnam, Jr, MD, FACS;David Royston, MD

October 1st 2003

Management of patients with neoplastic disease has shifted from searchand-destroy approaches employing radical surgery, chemotherapy,and radiotherapy to novel strategies that target specific molecular orgenetic characteristics or modify growth factors, angiogenesis, and cell-cell interactions.Attention has also been focused on modifying the production and function ofcertain enzymes pivotal to the genesis of disseminated disease.

Evaluating the Role of Serine Protease Inhibition in the Management of Tumor Micrometastases

Joe B. Putnam, Jr, MD, FACS;David Royston, MD;Ann F. Chambers, PhD;Scott Dunbar, MD;John H. Lemmer, Jr, MD;Peter Norman, MD;Elizabeth Travis, PhD;Ara A. Vaporciyan, MD;Stephen Yang, MD, FACS;Leo R. Zacharski, MD

October 1st 2003

Conservation of blood is apriority during surgery, owingto shortages of donor bloodand risks associated with transfusionof blood products.[9,10] However,blood transfusions have been linkedto a number of negative postoperativesequelae, including poorer prognosisafter cardiac and cancer surgery.[11-21] In this context, recognition thatallogeneic transfusion-associatedimmunomodulation can increasemorbidity in allogeneically transfusedpatients has become a major concernin transfusion medicine.[9,22,23]